专利检索 ap:("The Regents of the University of California") AND inv:"Jami McLaughlin Witte" 第 1 页

1.

发明申请
METHOD TO SEQUENCE MRNA IN SINGLE CELLS IN PARALLEL WITH QUANTIFICATION OF INTRACELLULAR PHENOTYPE 有权

公开(公告)号：US20220308061A1

公开(公告)日：2022-09-29

申请号：US17638092

申请日：2020-09-02

申请人： The Regents of the University of California

发明人： Owen N. Witte , Pavlo A. Nesterenko , Jami McLaughlin Witte

IPC分类号： G01N33/574 , C12Q1/6804 , G01N33/569 , C12Q1/6806

摘要： The disclosure provides methods and materials useful for obtaining novel TCR gene sequences that are useful in tumor-specific T cell receptor (TCR) gene transfer. Embodiments of the invention also include methods of crosslinking and permeabilizing mammalian cells that can, for example, be used in methods for obtaining novel TCR gene sequences. The disclosure further provides methods and materials useful for obtaining novel TCR gene sequences. Tumor-specific T cell receptor gene transfer enables specific and potent immune targeting of tumor and viral antigens, and for this reason is technology of significant interest to medical personnel.

2.

发明申请
COMPOSITION OF NY-ESO-1-SPECIFIC T CELL RECEPTORS RESTRICTED ON MULTIPLE MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES 有权

公开(公告)号：US20210324035A1

公开(公告)日：2021-10-21

申请号：US17273192

申请日：2019-09-04

申请人： The Regents of the University of California , California Institute of Technology , The Olivia Newton-John Cancer Research Institute

发明人： Owen N. Witte , Jami McLaughlin Witte , Antoni Ribas , Lili Yang , Michael T. Bethune , Jonathan Cebon , Katherine Woods , Ashley J. Knights , David Baltimore

IPC分类号： C07K14/725 , A61K35/17 , C12N15/86 , C12N5/0783 , A61P35/00

摘要： Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.